| |
|
|
|
Hyatt Regency Philadelphia at Penn's Landing, 201 South Christopher Columbus Blvd., Philadelphia, PA 19106
November 3-5, 2014
Cambridge Healthtech Institute's and the BioPharma Strategy Series' 12th Annual "Strategic Resource Management" and 9th Annual "Portfolio Management" will be held November 3-5, 2014 in Philadelphia, PA at the Hyatt Penn's Landing. Each year this executive forum attracts over 100 participants who help lead their organizations' resource management, portfolio management, innovation, decision analysis, R&D, forecasting and commercial strategies. Our 2014 meeting will build on last year's successful event with novel case studies and perspectives from thought leaders in pharma, biotech and device industries; cross-industries such as defense and IT; and public and governmental communities. We will again feature interactive breakout discussion groups, luncheon presentations, as well as an optional post-conference Project Portfolio Management Certification Master Class on Thursday and Friday. The three-day forum will cover the topics one should consider when managing resources and a diverse portfolio in today's economy.
|
|
|
|
|
|
|
|
Organized by:
|
|
Cambridge Healthtech Institute (CHI) |
|
|
Invited Speakers:
|
|
- John Ansell, Senior Partner, TranScrip Partners
- Sultan Aziz, Senior Director, Capacity Management, Janssen Pharmaceuticals
- Greg Bayer, Group Director, R&D Scheduling & Resource Management, Bristol-Myers Squibb
- Richard Bayney, Ph.D., President & Founder, Project & Portfolio Value Creation; former Vice President, Portfolio Management & Decision Analysis, Johnson & Johnson
- Pasquale Cetera, Consultant, MKTG Pharmaceuticals; former Vice President, Portfolio Management and Strategy, Merck
- Jeffrey Davis, M.D., Director, Human Health and Performance (HH&P), CMO, NASA Johnson Space Center
- Carmel Egan, Ph.D., Vice President, Project Management, Eli Lilly & Co.
- Philip Fahringer, Analyst, Center for Innovation, Lockheed Martin
- Jonathan Freeman, Ph.D., Senior Vice President, Head, Portfolio Management, Merck Serono
- Krish Ghosh, Ph.D., Vice President, Informatics, Covance
- Arkady Gusev, Ph.D., US Operations Head, Biomarker Development (BMD), Translational Medicine, Novartis Institutes for BioMedical Research, Inc.
- Ling He, Director, Clinical Bioanalysis, Daiichi Sankyo Pharma Dev
- Hartmut Hein, Ph.D., Director, Global Planning Office, Merck KGaA
- Rafiqul Islam, Senior Director, Global Bioanalytical Services, Celerion, Inc.
- Elayne Ko, Manager, Strategy Group, Siemens Health Services
- William Korinek, Ph.D., Vice President, Worldwide R&D Business Operations, Pfizer
- John LaMattina, Senior Partner, PureTech Ventures; former President of R&D, Pfizer
- Sam Mathew, MBA, Portfolio Capacity Management Leader, Finance/PMO, Janssen Pharmaceuticals
- Maureen McNamara, Executive Director, Global Project Management, Merck Research Laboratories
- Carlos Nunes, Director, Portfolio & Decision Analysis, Portfolio & Commercial Operations, Pfizer
- George Santangelo, Ph.D., Head, Office of Portfolio Analysis (OPA) , Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI), NIH
- Michael Shires, Vice President, Program and Portfolio Management, Baxter Healthcare
- Tom Stone, Director, Strategy, Siemens Health Services
- Bennet Vallet, Director, Product Development, Siemens
- Daniel Zweidler, Ph.D., Senior Fellow, Mack Institute for Innovation Management, The Wharton School, UPenn; President, DZA, Inc.
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
---
|
|
|
|
|
|
|
|
Registration:
|
|
Register Now
|
|
|
E-mail:
|
|
kwaterman@healthtech.com
|
|
|
|
|
|
|
|
|